Efficacy for ADHD symptoms (parents using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Efficacy for ADHD symptoms (teachers using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
CGI (response rate) ‐ desipramine and nortriptyline · Children and adolescents with ADHD
Tricyclic antidepressants (TCAs) may leads to higher CGI (response rate) ‐ desipramine and nortriptyline compared with placebo (low certainty).
1 finding from 1 review
Clinical global impression (response rate) ‐ desipramine · Children and adolescents with ADHD
Tricyclic antidepressants (TCAs) may leads to higher clinical global impression (response rate) ‐ desipramine compared with placebo (low certainty).
1 finding from 1 review
All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Leaving the study early · adults with panic disorder
Tricyclic antidepressants probably leads to lower total number of dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
Tricyclic antidepressants may leads to lower failure to remit compared with placebo (low certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review
Withdrawals due to adverse events · adults with panic disorder
Tricyclic antidepressants probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Tricyclic antidepressants probably leads to lower failure to respond compared with placebo (moderate certainty).
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Adverse events (at 4, 6 or 12 weeks) · adults with insomnia
Tricyclic antidepressants showed no clear difference in adverse events (at 4, 6 or 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Sleep onset latency ‐ not reported · adults with insomnia
1 finding from 1 review
Sleep efficiency · adults with insomnia
1 finding from 1 review
Total sleep time, next night; · adults with insomnia
1 finding from 1 review
Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use
It is very uncertain whether tricyclic antidepressants changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Tricyclic antidepressants may leads to higher benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review